<DOC>
	<DOCNO>NCT01417000</DOCNO>
	<brief_summary>Test safety , immune response efficacy GVAX pancreas vaccine ( cyclophosphamide ) CRS-207 compare GVAX pancreas vaccine ( cyclophosphamide ) alone adult fail refuse prior treatment metastatic pancreatic cancer .</brief_summary>
	<brief_title>Safety Efficacy Combination Listeria/GVAX Immunotherapy Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Have histologically proven malignant adenocarcinoma pancreas ; measurable disease require . ( Subjects mixed histology include predominant component adenocarcinoma . Subjects must metastatic disease . ) Have receive refuse least one chemotherapy regimen At least 18 year age ECOG 0 1 Anticipated life expectancy &gt; 12 week For woman men childbearing potential , medically acceptable method highly effective contraception ( oral hormonal contraceptive , condom plus spermicide , hormone implant ) must use throughout study period 28 day final vaccine administration . ( A barrier method contraception must employ subject [ male female ] , regardless method . ) Be willing able give write informed consent , able comply study procedure Have adequate organ function define specified laboratory value Currently history certain studyspecified heart , liver , kidney , lung , neurological , immune medical condition Known history evidence brain metastasis Have evidence hepatic cirrhosis clinical radiographic ascites Have clinically significant and/or malignant pleural effusion Known suspect hypersensitivity component GVAX Pancreas vaccine CRS207 , know allergy penicillin sulfa Received investigational product within 28 day study treatment plan receive within 28 day vaccine administration Used systemic steroid within 28 day study treatment Use 3 g/d acetaminophen Prosthetic joint artificial implant device easily remove ( exception ) Major surgery significant traumatic injury ( unhealed surgical wound ) occur within 28 day prior receive study drug , plan surgery require general anesthesia Infection HIV hepatitis B C screen Any immunodeficiency disease immunocompromised state active autoimmune disease history autoimmune disease require systemic steroid immunosuppressive treatment Be pregnant breastfeed Unable avoid close contact another individual know high risk listeriosis ( e.g. , newborn infant , pregnant woman , HIVpositive individual ) course CRS207 treatment completion antibiotic regimen Conditions , include alcohol drug dependence , intercurrent illness , lack sufficient peripheral venous access , would affect patient 's ability comply study visit procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Cancer vaccine</keyword>
	<keyword>Listeria monocytogenes</keyword>
	<keyword>Listeria-based vaccine</keyword>
	<keyword>GVAX</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>T regulatory cell</keyword>
	<keyword>Heterologous Prime-Boost</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Mesothelin</keyword>
	<keyword>Pancreatic cancer</keyword>
</DOC>